- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 3 - Provider Buy-in and Clinical Pathway Development
Dr Yu said that it is crucial for providers' voices to be heard in pathway development.
Dr Yu said that it is crucial for providers’ voices to be heard in pathway development.
“If you’re going to be successful, you need to have buy-in. If you need to have buy-in, you need to have people believe that it’s a transparent process of pathways development that they respect and feel that they had a voice in,” he explained.
He detailed how a healthcare setting can also impact pathway development, and the role that published medical literature has on the real-world setting practice. The actual experience of implementing pathways and patient behavior need to be closely monitored. There should also be feedback loops that include physicians.
Dr Tischler agreed, saying that provider buy-in is necessary. He said that for authentic buy-in, one cannot force a caregiver to act or practice in a certain way.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
